ABSTRACT
NAD, cytochrome c, and energostim modulated the fluorescence emission spectrum of trifluoperazine in the solution and in microsomal suspension. The data suggest that NAD and energostim modify structural and conformational characteristics of the dopamine receptor-trifluoperazine complex. These changes probably underlie the anticataleptic effect of energostim.
Subject(s)
Antioxidants/pharmacology , Catalepsy/prevention & control , Animals , Antioxidants/metabolism , Antipsychotic Agents/toxicity , Catalepsy/chemically induced , Catalepsy/metabolism , Cytochromes c/pharmacology , Male , Microsomes/drug effects , Microsomes/metabolism , NAD/pharmacology , Rats , Receptors, Dopamine/metabolism , Spectrometry, Fluorescence , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Trifluoperazine/toxicityABSTRACT
Administration of trifluoperazine in a single dose of 3 mg/kg induced catalepsy and locomotor disorders in 86% intact animals, which persisted for 4 h. Catalepsy developed in only 15% animals pretreated with antihypoxic and antioxidant agent energostim in a dose of 230 mg/kg. The protective effect of energostim was associated with its ability to maintain the balance between dopaminergic, cholinergic, and adrenal activity in the substantia nigra and medulla oblongata during administration of neuroleptics.
